The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Post-Traumatic Stress Disorder Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Post-Traumatic Stress Disorder Market.
Some of the key takeaways from the Post-Traumatic Stress Disorder Pipeline Report:
- Companies across the globe are diligently working toward developing novel Post-Traumatic Stress Disorder treatment therapies with a considerable amount of success over the years.
- Post-Traumatic Stress Disorder companies working in the treatment market are Bionomics Limited, Alto Neuroscience, Jazz Pharmaceuticals, Lundbeck, Atai Life Sciences, Aptinyx, Otsuka Pharmaceuticals, and others, are developing therapies for the Post-Traumatic Stress Disorder treatment
- Emerging Post-Traumatic Stress Disorder therapies in the different phases of clinical trials are- BNC210, ALTO-100, JZP150, Lu AG06466, EMP-01, NYX-783, Brexpiprazole, and others are expected to have a significant impact on the Post-Traumatic Stress Disorder market in the coming years.
- In Feb 2024, Curavit Clinical Research, a virtual contract research organization (VCRO) with expertise in decentralized clinical trials (DCTs) for digital therapeutics (DTx), effectively concluded a decentralized trial related to the Sana Device. Sana has forwarded the trial data for evaluation by the U.S. Food and Drug Administration (FDA) with the aim of obtaining Breakthrough Device Designation for its innovative wearable, virtual-reality-style mask. This device utilizes audiovisual stimulation to alleviate symptoms associated with post-traumatic stress disorder (PTSD).
- In May 2022, Madrigal Mental Care unveiled its nanotechnology aimed at addressing post-traumatic stress disorder (PTSD) treatment and prevention during the Biomed Israel event.
- In January 2022, Mydecine Innovations Group Inc. established a collaboration with Combat Stress and King’s College London to incorporate psilocybin within psychoactive-assisted psychotherapy, targeting the treatment of post-traumatic stress disorder (PTSD) specifically in veterans.
Post-Traumatic Stress Disorder Overview
Post-Traumatic Stress Disorder (PTSD) is a mental health condition that can develop after experiencing or witnessing a traumatic or distressing event. These events could involve threats of injury or death, serious accidents, natural disasters, combat, physical assault, or other life-threatening situations.
Get a Free Sample PDF Report to know more about Post-Traumatic Stress Disorder Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/post-traumatic-stress-disorder-ptsd-pipeline-insight
Emerging Post-Traumatic Stress Disorder Drugs Under Different Phases of Clinical Development Include:
- Lu AG06466: Lundbeck
- EMP-01: Atai Life Sciences
- BNC210: Bionomics Limited
- ALTO-100: Alto Neuroscienc
- JZP150: Jazz Pharmaceuticals
- NYX-783: Aptinyx
- Brexpiprazole: Otsuka Pharmaceuticals
Post-Traumatic Stress Disorder Route of Administration
Post-Traumatic Stress Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Post-Traumatic Stress Disorder Molecule Type
Post-Traumatic Stress Disorder Products have been categorized under various Molecule types, such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Post-Traumatic Stress Disorder Pipeline Therapeutics Assessment
- Post-Traumatic Stress Disorder Assessment by Product Type
- Post-Traumatic Stress Disorder By Stage and Product Type
- Post-Traumatic Stress Disorder Assessment by Route of Administration
- Post-Traumatic Stress Disorder By Stage and Route of Administration
- Post-Traumatic Stress Disorder Assessment by Molecule Type
- Post-Traumatic Stress Disorder by Stage and Molecule Type
DelveInsight’s Post-Traumatic Stress Disorder Report covers around 22+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Post-Traumatic Stress Disorder product details are provided in the report. Download the Post-Traumatic Stress Disorder pipeline report to learn more about the emerging Post-Traumatic Stress Disorder therapies
Some of the key companies in the Post-Traumatic Stress Disorder Therapeutics Market include:
Key companies developing therapies for Post-Traumatic Stress Disorder are – Merck KGaA, Pfizer Inc., Aurobindo Pharma, GlaxoSmithKline plc, Jazz Pharmaceuticals, Mydecine Innovations Group, Tonix Pharmaceuticals, Otsuka Pharmaceutical Co., Ltd., Lupin Limited, Teva Pharmaceutical, Viatris Inc., Jubilant Pharmova, and others.
Post-Traumatic Stress Disorder Pipeline Analysis:
The Post-Traumatic Stress Disorder pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Post-Traumatic Stress Disorder with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Post-Traumatic Stress Disorder Treatment.
- Post-Traumatic Stress Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Post-Traumatic Stress Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Post-Traumatic Stress Disorder market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Post-Traumatic Stress Disorder drugs and therapies
Post-Traumatic Stress Disorder Pipeline Market Drivers
- Increase in prevalence, increased initiatives to create public awareness and knowledge of disease are some of the important factors that are fueling the Post-Traumatic Stress Disorder Market.
Post-Traumatic Stress Disorder Pipeline Market Barriers
- However, heterogeneity of the symptoms, delayed-onset PTSD and other factors are creating obstacles in the Post-Traumatic Stress Disorder Market growth.
Scope of Post-Traumatic Stress Disorder Pipeline Drug Insight
- Coverage: Global
- Key Post-Traumatic Stress Disorder Companies: Bionomics Limited, Alto Neuroscienc, Jazz Pharmaceuticals, Lundbeck, Atai Life Sciences, Aptinyx, Otsuka Pharmaceuticals, and others
- Key Post-Traumatic Stress Disorder Therapies: BNC210, ALTO-100, JZP150, Lu AG06466, EMP-01, NYX-783, Brexpiprazole, and others
- Post-Traumatic Stress Disorder Therapeutic Assessment: Post-Traumatic Stress Disorder current marketed and Post-Traumatic Stress Disorder emerging therapies
- Post-Traumatic Stress Disorder Market Dynamics: Post-Traumatic Stress Disorder market drivers and Post-Traumatic Stress Disorder market barriers
Request for Sample PDF Report for Post-Traumatic Stress Disorder Pipeline Assessment and clinical trials
Table of Contents
1. Post-Traumatic Stress Disorder Report Introduction
2. Post-Traumatic Stress Disorder Executive Summary
3. Post-Traumatic Stress Disorder Overview
4. Post-Traumatic Stress Disorder- Analytical Perspective In-depth Commercial Assessment
5. Post-Traumatic Stress Disorder Pipeline Therapeutics
6. Post-Traumatic Stress Disorder Late Stage Products (Phase II/III)
7. Post-Traumatic Stress Disorder Mid Stage Products (Phase II)
8. Post-Traumatic Stress Disorder Early Stage Products (Phase I)
9. Post-Traumatic Stress Disorder Preclinical Stage Products
10. Post-Traumatic Stress Disorder Therapeutics Assessment
11. Post-Traumatic Stress Disorder Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Post-Traumatic Stress Disorder Key Companies
14. Post-Traumatic Stress Disorder Key Products
15. Post-Traumatic Stress Disorder Unmet Needs
16 . Post-Traumatic Stress Disorder Market Drivers and Barriers
17. Post-Traumatic Stress Disorder Future Perspectives and Conclusion
18. Post-Traumatic Stress Disorder Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/